Literature DB >> 11157899

Molecular diversity of quinolone resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones.

G Y Guirao1, M C Martínez Toldos, B Mora Peris, M A Alonso Manzanares, M N Gutiérrez Zufiaurre, J A Martínez Andrés, J L Muñoz Bellido, J A García-Rodríguez, M Segovia Hernández.   

Abstract

The genes encoding topoisomerases (gyrA and grlA) and the norA promoter of 100 fluoroquinolone-susceptible and -resistant Staphylococcus aureus clinical isolates obtained in two geographically distant hospitals were analysed. The relationship between mutations found and the susceptibility to newer quinolones was determined. Thirty-nine strains were grouped in seven clones by pulsed-field gel electrophoresis (PFGE). The remaining 61 strains were classified as unrelated strains. In three clones, all strains showed the same grlA-gyrA-norA mutation profiles. Strains in the rest of the groups showed different mutation profiles, even though PFGE indicated that they possessed genetically similar populations. One cluster showed a high level of diversity; five different mutation profiles were detected in the six isolates belonging to this pattern. Two isolates had a Glu84 to Lys mutation in grlA and another isolate had this mutation combined with a Ser84 to Leu mutation in gyrA. Combination of a Ser80 to Phe mutation in grlA and a Ser84 to Leu in gyrA was found in the two other isolates. One of these also had a thymine to a guanine transversion at a position 89 nucleotides upstream of the norA start codon in the norA promoter. These results show that fluoroquinolone resistance in clinical S. aureus strains does not necessarily result from the spread of resistant clones. Fluoroquinolone resistance may develop independently in strains belonging to the same PFGE pattern by accumulation of different mutations over a quinolone-susceptible ancestor wild type or single grlA mutant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157899     DOI: 10.1093/jac/47.2.157

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

2.  Antibiotic resistance, biochemical typing, and PFGE typing of Bifidobacterium strains commonly used in probiotic health foods.

Authors:  Feili Xu; Junping Wang; Yunchang Guo; Ping Fu; Huawei Zeng; Zhigang Li; Xiaoyan Pei; Xiumei Liu; Shuo Wang
Journal:  Food Sci Biotechnol       Date:  2018-02-12       Impact factor: 2.391

3.  Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Philip Chung; Patrick J McNamara; William B Titlow; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  Prevalence and Genetic Basis of Antimicrobial Resistance in Non-aureus Staphylococci Isolated from Canadian Dairy Herds.

Authors:  Diego B Nobrega; Sohail Naushad; S Ali Naqvi; Larissa A Z Condas; Vineet Saini; John P Kastelic; Christopher Luby; Jeroen De Buck; Herman W Barkema
Journal:  Front Microbiol       Date:  2018-02-16       Impact factor: 5.640

5.  Multidrug Efflux Pumps in Staphylococcus aureus: an Update.

Authors:  Sofia Santos Costa; Miguel Viveiros; Leonard Amaral; Isabel Couto
Journal:  Open Microbiol J       Date:  2013-03-22

6.  Resistance to Antimicrobials Mediated by Efflux Pumps in Staphylococcus aureus.

Authors:  Sofia S Costa; Elisabete Junqueira; Cláudia Palma; Miguel Viveiros; José Melo-Cristino; Leonard Amaral; Isabel Couto
Journal:  Antibiotics (Basel)       Date:  2013-03-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.